Literature DB >> 32945109

Unusual lung involvements of invasive mucinous adenocarcinoma with chylothorax.

Ayako Aoki1, Yu Hara1, Koji Okudela2, Yoshihiro Ishikawa3, Kosei Doshita1, Hisashi Hashimoto1, Kentaro Nakashima1, Nobuyuki Horita1, Nobuaki Kobayashi1, Takeshi Kaneko1.   

Abstract

A 77-year-old man who had a persistent productive cough for one month was admitted to our hospital. Chest computed tomography (CT) revealed subpleural nodular opacities, irregular pleural thickening with bilateral basal predominance, and a small right pleural effusion. Aspirated fluid was exudative and had the appearance of chylothorax without malignant cells. Surgical lung biopsy specimen showed focal proliferation of neoplastic epithelial cells with lepidic-predominant pattern and abundant mucus in the alveolar spaces, consistent with invasive mucinous adenocarcinoma (IMA). The results of PD-L1 expression and the EGFR, ALK, ROS1, and BRAF mutation status analyzed by next generation sequencer were all negative. IMA should be considered in the differential diagnosis of subpleural micronodular opacities accompanied by pleural effusion (chylothorax) on chest CT. KEY POINTS: Significant findings of the study This case showed subpleural micronodular opacities and chylothorax as unusual chest computed tomography (CT) patterns for invasive mucinous adenocarcinoma (IMA). What this study adds Invasive mucinous adenocarcinoma (IMA) should be considered in the differential diagnosis of subpleural micronodular opacities accompanied by pleural effusion on chest CT.
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Chylothorax; computed tomography; invasive mucinous adenocarcinoma

Mesh:

Year:  2020        PMID: 32945109      PMCID: PMC7605987          DOI: 10.1111/1759-7714.13665

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


A 77‐year‐old man with a history of a persistent productive cough for one month was admitted to our hospital. Chest computed tomography (CT) revealed subpleural nodular opacities, irregular pleural thickening with bilateral basal predominance, and a small right pleural effusion (Fig 1). The differential diagnosis included diffuse pan‐bronchiolitis, mycobacterium infection, pulmonary sarcoidosis, and lymphoma; however, there was no increase in blood angiotensin‐converting enzyme or carcinoma‐specific tumor markers including carcinoembryonic antigen, squamous cell carcinoma antigen, cytokeratin 19 fragment, neuron specific enolase, sialyl lewis X‐i antigen, or soluble interleukin‐2 receptor; and no evidence of specific pathogens or malignant cells in the sputum. After administration of macrolide and new quinolone antibiotics, the pleural effusion worsened slightly and lung involvement became more apparent. Aspirated fluid was exudative (protein; 2.8 g/dl, lactate dehydrogenase; 331 mg/dL), with a total cell count of 775/μL and lymphocyte predominance. It also had the appearance of chylothorax, with elevated triglyceride levels (160 mg/dL [pleural effusion] vs. 128 mg/dL [blood]) and without malignant cells. Although 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (18F‐PET‐CT) revealed no remarkable FDG uptake, surgical lung biopsy was performed to obtain a definitive diagnosis of lung involvement. The histological specimen showed focal proliferation of neoplastic epithelial cells with lepidic‐predominant pattern and abundant mucus in the alveolar spaces (Fig 2). Immunohistochemical results were CK7 (+), TTF‐1 (−), CK20 (−), HNF‐1α (−), and Ki‐67 (≥30%), consistent with invasive mucinous adenocarcinoma (IMA). The results of PD‐L1 expression and the EGFR, ALK, ROS1, and BRAF mutation status analyzed by next‐generation sequencing (NGS) were all negative.
Figure 1

Chest computed tomography. Subpleural nodular opacities and irregular pleural thickening are seen with bilateral basal predominance. A small right‐sided pleural effusion is also observed.

Figure 2

Surgical lung biopsy specimen. Histologically, the specimen showed focal proliferation of neoplastic epithelial cells with lepidic‐predominant pattern (black circles) and abundant mucus in the alveolar spaces.

Chest computed tomography. Subpleural nodular opacities and irregular pleural thickening are seen with bilateral basal predominance. A small right‐sided pleural effusion is also observed. Surgical lung biopsy specimen. Histologically, the specimen showed focal proliferation of neoplastic epithelial cells with lepidic‐predominant pattern (black circles) and abundant mucus in the alveolar spaces. Typical CT findings of IMA of the lung are a mass‐like opacity or consolidation mimicking lobar pneumonia. , , However, this case showed a very rare CT pattern of subpleural micronodular opacities that was difficult to identify as lung carcinoma. Moreover, this case was accompanied by chylothorax due coincidentally to tumor progression. Therefore, IMA should be considered in the differential diagnosis of subpleural micronodular opacities accompanied by pleural effusion on chest CT.

Disclosure

None of the authors have any real or perceived conflicts of interest to declare in relation to this manuscript.
  3 in total

1.  Acinar-Predominant Pattern Correlates With Poorer Prognosis in Invasive Mucinous Adenocarcinoma of the Lung.

Authors:  Gengpeng Lin; Hui Li; Jianyi Kuang; Kejing Tang; Yubiao Guo; Anjia Han; Canmao Xie
Journal:  Am J Clin Pathol       Date:  2018-03-29       Impact factor: 2.493

2.  Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.

Authors:  Katsuhiko Shimizu; Riki Okita; Shinsuke Saisho; Ai Maeda; Yuji Nojima; Masao Nakata
Journal:  Onco Targets Ther       Date:  2016-12-28       Impact factor: 4.147

3.  Comparing clinicopathological features and prognosis of primary pulmonary invasive mucinous adenocarcinoma based on computed tomography findings.

Authors:  Kai Nie; Wei Nie; Yu-Xuan Zhang; Hong Yu
Journal:  Cancer Imaging       Date:  2019-07-10       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.